Form 8-K/A CYTOKINETICS INC For: Jul 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Cytokinetics' (CYTK) Redwood-HCM Top-line Results 'Deliver on All Fronts' - Analyst
July 19, 2021 1:58 PM EDTEarlier today, Cytokinetics, Inc (NASDAQ: CYTK) announced positive topline results from Cohorts 1 and 2 of Redwood-HCM - the Phase 2 clinical trial of CK-3773274 (CK-274), an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM).
Throughout the trial, the CK-274 demonstrated high response rates, significant treatment effects and a favorable safety profile, reporting no serious adverse events attributable to CK-274 and no treatment interruptions occurring.
Reacting to the data readout, H.C. Wainwright & Co's analyst Joseph Pantginis believes the drug delivered on all fronts as expected and demonstrates... More
Cytokinetics (CYTK) PT Raised to $53 at H.C. Wainwright
July 19, 2021 12:27 PM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $53.00 (from $41.00) while maintaining a Buy rating.
... More